SLC6A1 Protein — GABA Transporter 1

SLC6A1 Protein — GABA Transporter 1

Introduction

Slc6A1 Protein — Gaba Transporter 1 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

<div class="infobox infobox-protein">
<h3>SLC6A1 Protein</h3>
<table>
<tr><th>Protein Name</th><td>Solute Carrier Family 6 Member 1 (GABA Transporter 1)</td></tr>
<tr><th>Gene</th><td>[SLC6A1](/genes/slc6a1)</td></tr>
<tr><th>UniProt ID</th><td>[P30531](https://www.uniprot.org/uniprot/P30531)</td></tr>
<tr><th>Protein Size</th><td>599 amino acids (~63 kDa)</td></tr>
<tr><th>Subcellular Localization</th><td>Plasma membrane; presynaptic terminals</td></tr>
<tr><th>Protein Family</th><td>SLC6 family (Sodium:neurotransmitter symporters, SSS)</td></tr>
<tr><th>PDB Structures</th><td>[6WE7](https://www.ebi.ac.uk/pdbe/search/pdb/6WE7), [5U75](https://www.ebi.ac.uk/pdbe/search/pdb/5U75)</td></tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
</div>

SLC6A1 (GABA Transporter 1, GAT-1) is a sodium-dependent GABA transporter that regulates GABA signaling in the brain by reuptaking GABA into [neurons](/entities/neurons) and glia. It plays critical roles in inhibitory neurotransmission and is implicated in epilepsy and other neurological disorders.

Structure

SLC6A1 has the classic SLC6 transporter fold:

SLC6A1 Protein — GABA Transporter 1

Introduction

Slc6A1 Protein — Gaba Transporter 1 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

<div class="infobox infobox-protein">
<h3>SLC6A1 Protein</h3>
<table>
<tr><th>Protein Name</th><td>Solute Carrier Family 6 Member 1 (GABA Transporter 1)</td></tr>
<tr><th>Gene</th><td>[SLC6A1](/genes/slc6a1)</td></tr>
<tr><th>UniProt ID</th><td>[P30531](https://www.uniprot.org/uniprot/P30531)</td></tr>
<tr><th>Protein Size</th><td>599 amino acids (~63 kDa)</td></tr>
<tr><th>Subcellular Localization</th><td>Plasma membrane; presynaptic terminals</td></tr>
<tr><th>Protein Family</th><td>SLC6 family (Sodium:neurotransmitter symporters, SSS)</td></tr>
<tr><th>PDB Structures</th><td>[6WE7](https://www.ebi.ac.uk/pdbe/search/pdb/6WE7), [5U75](https://www.ebi.ac.uk/pdbe/search/pdb/5U75)</td></tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
</div>

SLC6A1 (GABA Transporter 1, GAT-1) is a sodium-dependent GABA transporter that regulates GABA signaling in the brain by reuptaking GABA into [neurons](/entities/neurons) and glia. It plays critical roles in inhibitory neurotransmission and is implicated in epilepsy and other neurological disorders.

Structure

SLC6A1 has the classic SLC6 transporter fold:

• 12 Transmembrane Domains: Alpha-helices that form the translocation pathway
• N-terminal and C-terminal Intracellular Loops: Important for trafficking and regulation
• Sodium Binding Sites: Multiple Na+ binding sites required for transport
• GABA Binding Site: Central binding pocket that alternates between outward- and inward-facing conformations
• Chloride Ion Binding Site: Cl- ions are co-transported with GABA and Na+

Normal Function

GAT-1 performs essential functions in GABAergic signaling:

Role in Disease

Epilepsy

• GAT-1 dysfunction contributes to epilepsy pathogenesis
• Reduced GAT-1 function leads to impaired GABA clearance and hyperexcitability
• GAT-1 knockout mice exhibit spontaneous seizures
• Tiagabine (GAT-1 inhibitor) can cause seizures as side effect

Myoclonic Atonic Epilepsy (MAE)

• SLC6A1 mutations cause a spectrum of epileptic encephalopathies
• Affected individuals have myoclonic-astatic seizures
• Developmental delay and intellectual disability common

Alzheimer's Disease

• Altered GAT-1 expression in AD brains may contribute to network dysfunction
• GABAergic dysfunction correlates with cognitive decline
• Targeting GAT-1 explored as therapeutic approach

Parkinson's Disease

• GAT-1 in basal ganglia regulates inhibitory output
• Modulation affects motor symptoms
• GAT-1 inhibitors explored as adjunct therapy

Therapeutic Targeting

GAT-1 is a proven therapeutic target:

• Tiagabine: Selective GAT-1 inhibitor used as anticonvulsant
• Nirmezumab: Anti-GAT-1 antibody being investigated for epilepsy
• Small Molecule Modulators: GAT-1 enhancers for cognitive enhancement

Interactions

SLC6A1 interacts with:

• GABA: Primary substrate
• Sodium (Na+): Required co-transport ion
• Chloride (Cl-): Co-transported ion
• Protein Kinases: PKC regulates transporter activity
• Neuronal Interactors: Synaptic scaffolding proteins for localization

See Also

• [SLC6A1 Gene](/genes/slc6a1)
• [GABA Signaling in the Brain](/mechanisms/gaba-signaling-pathway)
• [GABA Transporters](/mechanisms/gaba-transporters)
• [Epilepsy Genes](/diseases/epilepsy)
• [Inhibitory Neurotransmission](/mechanisms/inhibitory-neurotransmission)

Background

The study of Slc6A1 Protein — Gaba Transporter 1 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
• [Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/) - Research data
• [Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data

References

PMID: 7520906(https://pubmed.ncbi.nlm.nih.gov/7520906/)